Marker Therapeutics Inc. has published a document discussing the effects of lymphodepletion on Multi-Antigen Recognizing $(MAR)$-T cells in patients with lymphoma. The document highlights that lymphodepletion enhances the expansion and persistence of MT-601 T cell clones, as shown by preliminary data from the Phase 1 APOLLO study. The data suggest that participants undergoing lymphodepletion exhibit significantly higher levels of MAR-T cell clone expansion compared to those who did not. The full document can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.